tocilizumab,doxorubicin,ibrutinib,prednisone,obinutuzumab,rituximab,glofitamab,cyclophosphamide
teva,roche,abbvie,janssen,sopherion
['doxorubicin', 'triangle', 'dlbcl', 'np30179', 'mantle,(-dismantle)', 'lymphoma', 'obinu', 'prednisone', 'glofitamab', 'cyclophosphamide', 'lymsm', 'nhl', 'ritux']
congress | ash22 discusses the risk of crs with glofitamab as predicted by an updated prediction model. in aggressive histologies, the crs-rs.5p model showed identical performance with the previous crs-rs model &amp; may be used to inform clinical decision making #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm